Shares of Absci Corporation (NASDAQ:ABSI – Get Free Report) have been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $7.58.
A number of equities analysts have commented on ABSI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Absci in a research note on Monday, April 20th. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 price target on shares of Absci in a report on Wednesday, March 25th. Finally, Truist Financial raised their price objective on Absci from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Friday, May 8th.
View Our Latest Stock Analysis on ABSI
Key Absci News
- Positive Sentiment: HC Wainwright raised longer-term earnings estimates, including FY2028 EPS to $0.11 from $0.10, FY2029 EPS to $0.09 from $0.08, and FY2030 EPS to $0.64 from $0.61, suggesting improving profitability farther out. Absci analyst estimates
- Positive Sentiment: The analyst also slightly improved FY2026 EPS estimates to a smaller loss of ($0.84) from ($0.87), and nudged Q3/Q4 2026 estimates up to ($0.22) each from ($0.23), which may be seen as incremental progress. Absci analyst estimates
- Neutral Sentiment: HC Wainwright kept its near-term view cautious, forecasting continued losses in Q1 2027 and Q2 2027, with only a modest profit expected in Q3 2027 before a projected loss again in Q4 2027. Absci analyst estimates
- Negative Sentiment: Despite the estimate bumps, Absci is still expected to lose money in the next several quarters, and its current full-year consensus remains negative, which can weigh on investor sentiment. Absci analyst estimates
Absci Trading Down 1.1%
NASDAQ:ABSI opened at $5.30 on Thursday. The company has a market cap of $826.27 million, a price-to-earnings ratio of -6.39 and a beta of 2.36. Absci has a twelve month low of $2.24 and a twelve month high of $6.72. The stock has a fifty day simple moving average of $3.52 and a 200-day simple moving average of $3.34.
Absci (NASDAQ:ABSI – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. Absci had a negative net margin of 6,450.76% and a negative return on equity of 66.32%. The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $1.39 million. As a group, equities research analysts predict that Absci will post -0.82 EPS for the current fiscal year.
Insider Activity
In other news, insider Andreas Busch purchased 100,000 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were purchased at an average price of $2.29 per share, for a total transaction of $229,000.00. Following the completion of the purchase, the insider owned 421,446 shares in the company, valued at approximately $965,111.34. This represents a 31.11% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.49% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC lifted its position in shares of Absci by 21.1% in the 3rd quarter. ARK Investment Management LLC now owns 12,162,773 shares of the company’s stock worth $36,975,000 after purchasing an additional 2,116,845 shares during the period. Heights Capital Management Inc. purchased a new position in Absci during the third quarter valued at approximately $6,081,000. AXQ Capital LP purchased a new position in Absci during the third quarter valued at approximately $173,000. Rhumbline Advisers raised its stake in Absci by 11.7% in the third quarter. Rhumbline Advisers now owns 171,499 shares of the company’s stock worth $521,000 after buying an additional 17,945 shares in the last quarter. Finally, Stratos Wealth Partners LTD. purchased a new stake in Absci during the third quarter worth $32,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.
Absci Company Profile
Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.
The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.
Read More
- Five stocks we like better than Absci
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
